{"schema_version":"secwatch.filing_event.v1","accession":"0001217234-26-000038","form_type":"8-K","ticker":"CDNA","cik":"0001217234","company_name":"CareDx, Inc.","filed_at":"2026-07-07T21:12:41+00:00","discovered_at":"2026-07-07T21:14:00.568087+00:00","generated_at":"2026-07-07T21:14:09.565558+00:00","sec_items":["2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+","bullets":["Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.","Acquisition of Naveris closed July 1 for $161.8M cash plus up to $100M earnout based on 2026-2027 revenue milestones.","Naveris' NavDx test is the only Medicare-covered MRD test for HPV+ head/neck and anal cancers; 130K+ tests reported.","Naveris generated ~$35M revenue in 2025, more than doubling YoY; ADLT reimbursement rate of $1,800 per test.","Combined estimated U.S. addressable market exceeds $12B across transplant, specialty oncology, and cell therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001217234-26-000038","json":"https://secwatch.observer/filing/0001217234-26-000038.json","markdown":"https://secwatch.observer/filing/0001217234-26-000038.md","text":"https://secwatch.observer/filing/0001217234-26-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/0001217234-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1217234/000121723426000038/cdna-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T21:14:09.565558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}